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Abstract: We are currently assisting in the explosion of epitranscriptomics, which studies the
functional role of chemical modifications into RNA molecules. Among more than 100 RNA
modifications, the N6-methyladenosine (m6A), in particular, has attracted the interest of researchers
all around the world. m6A is the most abundant internal chemical modification in mRNA, and it can
control any aspect of mRNA post-transcriptional regulation. m6A is installed by “writers”, removed
by “erasers”, and recognized by “readers”; thus, it can be compared to the reversible and dynamic
epigenetic modifications in histones and DNA. Given its fundamental role in determining the way
mRNAs are expressed, it comes as no surprise that alterations to m6A modifications have a deep
impact in cell differentiation, normal development and human diseases. Here, we review the proteins
involved in m6A modification in mammals, m6A role in gene expression and its contribution to
cancer development. In particular, we will focus on acute myeloid leukaemia (AML), which provides
an initial indication of how alteration in m6A modification can disrupt normal cellular differentiation
and lead to cancer.
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1. Introduction
Leukaemogenesis is caused by gene mutations and chromosomal aberrations resulting in changes
of gene expression and, eventually, alteration of cell growth/differentiation programs [1]. Over the
past decades, epigenetic modifications (e.g., DNA methylation and histone modifications) have been
shown to play a significant role in this process and are now recognized as targets of therapy for
different types of leukaemia and other haematological malignancies [2]. More recently, researchers
have identified a new layer of gene expression regulation at the RNA levels that consists of reversible
chemical modification of messenger RNAs (mRNAs), which led to the birth of the emerging field
of “epitranscriptomics” [3,4]. Among more than 100 chemical modifications that can occur within
various type of RNA molecules, N6-methyladenosine (m6A) is the most abundant internal chemical
modification of mRNA and is the one with the greatest impact on its dynamic regulation. The m6A
modification is installed by “writers” and removed by “erasers”; in addition, it can recruit specific
“reader” proteins. m6A modification and the associated regulatory proteins play a critical role in
gene expression by affecting different steps of the mRNA life, including splicing, nuclear export,
stability and translation [4,5]. The reversible and dynamic nature of m6A modification and its ability
to fine-tune and coordinate gene expression programs has attracted the interest of many research
groups in order to define its contribution to cell differentiation, normal development and human
diseases [4]. In particular, it has been shown that deregulation of m6A modification alters embryonic
stem cell maintenance and differentiation [4]. As acquisition of stem cell properties and defects in
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cell differentiation are common features of many cancers, this indicates that alterations of m6A levels
might have an important role in cancer development.
In this review, we describe the mammalian proteins involved in m6A modification and the effect
of the latter on mRNA expression. In particular, we will focus on the role of m6A in acute myeloid
leukaemia (AML), which provides an initial indication of how alteration in m6A levels can disrupt
normal cellular differentiation and contribute to carcinogenesis.
2. m6A Writers, Erasers and Readers
In mammalian cells, about 0.4% of adenosines inside mRNAs are m6A-modified (1–5 m6A sites
per transcript) [4,5]. The main complex responsible for m6A modifications of mRNAs is composed of
the methyltransferase-like protein 3 (METTL3) and the methyltransferase-like protein 14 (METTL14).
This core heterodimeric complex specifically methylates the adenosine within the DRACH motif
(D = A/G/U, R = A/G; H = A/C/U) (Figure 1). METTL3 is the catalytic component of the
complex while METTL14 is required for structural stabilization and RNA binding [6–8]. In vivo,
the activity of METTL3/METTL14 is regulated by an additional complex (referred to as MACOM,
m6A-METTL-associated complex) composed of Wilms tumor 1-associated protein (WTAP), Vir-like
m6A methyltransferase-associated (VIRMA, also known as KIAA1429), Cbl proto-oncogene-like
1 (CBLL1, also known as Hakai), RNA-binding motif 15 (RBM15), and zinc finger CCCH-type
containing 13 (ZC3H13) proteins [5] (Table 1). Notably, the percentage of m6A sites is lower than
the occurrence of the consensus motif, indicating that the core methylation complex is specifically
recruited by the MACOM complex on specific sites within mRNAs. In particular, modified adenosines
are specifically enriched in regions adjacent to the stop codon, 3′-UTR (Untranslated region) and within
long internal exons [9,10]. It is very likely that additional cell-specific regulators of m6A modification
still need to be identified.
Table 1. Mammalian m6A (N6-methyladenosine) regulators.
Protein Classification Function
METTL3 Writer Installs m6A in mRNA; promotes translation
METTL14 Writer Cooperates with METTL3 in m6A installation
METTL16 Writer Installs m6A in U6 snRNA and pre-mRNA
FTO Eraser Remove m6A and m6Am from mRNA
ALKBH5 Eraser Remove m6A from mRNA
WTAP Component of the regulatory MACOM complex Regulates m6A installation
VIRMA Component of the regulatory MACOM complex Regulates m6A installation
CBLL1 Component of the regulatory MACOM complex Regulates m6A installation
RBM15 Component of the regulatory MACOM complex Regulates m6A installation
ZC3H13 Component of the regulatory MACOM complex Regulates m6A installation
ABCF1 Direct reader Stimulates translation
eIF3 Direct reader Stimulates translation
HNRPA2B1 Direct reader Stimulates microRNA processing
IGF2BPs Direct readers Increase mRNA stability
YTHDC1 Direct reader Stimulates splicing and mRNA export
YTHDC2 Direct reader Stimulates mRNA decay and translation
YTHDF1 Direct reader Stimulates translation
YTHDF2 Direct reader Stimulates mRNA decay
YTHDF3 Direct reader Stimulates mRNA decay and translation
FMR1 Indirect reader Inhibits translation
HNRNPC Indirect reader Regulates splicing
ELAVL1 m6A repelled protein Increases mRNA stability
G3BPs m6A repelled protein Increase mRNA stability
m6A modification is essential for embryonic development. Deletion of METTL3 in mice is
embryonic lethal. Moreover, the importance of m6A is further shown by the fact that the complete
ablation of METTL3 and METTL14 in mESCs (mouse embryonic stem cells) impairs the transition
of naïve mESCs into the primed state and blocks the subsequent differentiation [11,12]. Similarly,
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deletion in mice of the regulatory MACOM complex components, WTAP and RBM15, produced
embryonic lethality [13–15].
More recently, the U6 snRNA m6A methyltransferase-like protein 16 (METTL16) has been shown
to target intronic regions of pre-mRNAs and lncRNAs (Long non-coding RNA) [16–18]. METTL16
binding sites do not overlap with that one of the METTL3/METTL14 methylation complex, indicating
independent functions in m6A modification. However, METTL16 plays an important role in regulating
the cellular homeostasis of the methyl donor SAM (S-adenosylmethionine) [16–18], thereby indirectly
contributing to global cellular methylation.
m6A marks within transcripts can be removed by the alkB homologue 5 (ALKBH5) and fat
mass and obesity-associated (FTO) proteins (Figure 1). These two proteins mainly localized to the
nuclear compartment where the removal of m6A modification occurs. FTO has an additional role
in demethylating the N6-2′-O-dimethyladenosine (m6Am) modification close to the mRNA CAP.
This modification is installed by a still-unknown modifying enzyme and has an independent role
from m6A in mRNA stability [19]. In mouse, these two enzymes have different tissue distributions,
with FTO being enriched in the brain and ALKBH5 in the testes, suggesting that they can have diverse
biological functions and can potentially affect different subsets of target mRNAs. Consistent with
their different in vivo expression, ALKBH5 KO (knock-out) mice show impaired male fertility [20],
while FTO KO mice exhibit increased postnatal death and reduced body mass [21].
The biological function of m6A is largely mediated by m6A reader proteins (Table 1). The YT521-B
homology (YTH) domain family of proteins (YTHDF1, YTHDF2, YTHDF3, YTHDC1 and YTHDC2),
which contain an aromatic cage for specifically accommodating the m6A, were among the first to
be identified [22]. In addition, m6A modification can induce structural alterations in transcripts,
which either favor or abolish the interaction of specific RNA binding proteins [23].
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Figure 1. m6A modification is installed by the core METTL3/METTL14 (methyltransferase-like protein 
3/methyltransferase-like protein 14) catalytic complex and erased by the two demethylases FTO (fat 
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Figure 1. m6A modification is installed by the core METTL3/METTL14 (methyltransferase-like
protein 3/methyltransferase-like protein 14) catalytic complex and erased by the two demethylases
FTO (fat mass and obesity-associated) and ALKBH5 (alkB homologue 5). The MACOM complex,
composed of WTAP (Wilms tumor 1-associated protein), RBM15 (RNA-binding motif 15), VIRMA
(Vir-like m6A methyltransferase-associated), ZC3H13 (zinc finger CCCH-type containing 13) and
CBLL1 (Cbl proto-oncogene like 1), guides the core complex on specific mRNAs and contributes to
select specific sites within single mRNA.
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3. m6A Effects on Gene Expression
m6A mediates its biological effects by influencing mRNA synthesis and function (Figure 2).
Different biological functions of m6A modification are carried out by readers. During transcription,
m6A is deposited on nascent RNA near splice junctions and within intronic regions [24,25].
The co-transcriptional nature of the m6A modification was also confirmed by CLIP (cross-linked
immunoprecipitation) experiments in which METTL3 and METTL4 were found associated with
intronic regions [26]. Due to its dynamic feature, the distribution of m6A peaks is cell type specific
and, eventually, also depends on developmental stages and changes in the environment. The core
m6A methylation complex and the regulatory MACOM complex localize predominantly in nuclear
speckles, where the mRNA splicing reaction occurs. Indeed, m6A levels modulate alternative splicing
by direct and indirect mechanisms. The nuclear reader YTHDC1 directly binds to m6A modified
pre-mRNAs and regulates splicing by recruiting the SR protein SRSF3 (Serine and arginine-rich
splicing factor 3). By contrast, the splicing regulator SRSF10 is repelled by m6A modified regions [27].
The hnRNP protein HNRNPA2B1 also mediates alternative splicing by directly binding m6A modified
pre-mRNA [28]. HNRNPA2B1 binding also stimulates the processing of microRNAs from host
pre-mRNA introns [28,29]. In addition, m6A modified regions can undergo conformational changes,
referred to as an “m6A switch”, favoring the interaction with RNA binding proteins, as in the case of
the splicing regulator HNRNPC [30].
Int. J. Mol. Sci. 2018, 19, x FOR PEER REVIEW  4 of 12 
 
methyltransferase-associated), ZC3H13 (zinc finger CCCH-type containing 13) and CBLL1 (Cbl 
proto-oncogene like 1), guides the core complex on specific mRNAs and contributes to select specific 
sites within single mRNA. 
3. m6A Effects on Gene Expression 
m6A mediates its biological effects by influencing mRNA synthesis and function (Figure 2). 
Different biological functions of m6A modification are carried out by readers. During transcription, 
m6A is deposited on nascent RNA near splice junctions and within intronic regions [24,25]. The co-
transcriptional nature of the m6A modification was also confirmed by CLIP (cross-linked 
immunoprecipitation) experiments in which METTL3 and METTL4 were found associated with 
intronic regions [26]. Due to its dynamic feature, the distribution of m6A peaks is cell type specific 
and, eventually, also depends on developmental stages and changes in the environment. The core 
m6A methylation complex and the regulatory MACOM complex localize predominantly in nuclear 
speckles, where the mRNA splicing reaction occurs. Indeed, m6A levels modulate alternative splicing 
by direct and indirect mechanisms. The nuclear reader YTHDC1 directly binds to m6A modified pre-
mRNAs and regulates splicing by recruiting the SR protein SRSF3 (Serine and arginine-rich splicing 
factor 3). By contrast, the splicing regulator SRSF10 is repelled by m6A modified regions [27]. The 
hnRNP protein HNRNPA2B1 also mediates alternative splicing by directly binding m6A modified 
pre-mRNA [28]. HNRNPA2B1 binding also stimulates the processing of microRNAs from host pre-
mRNA introns [28,29]. In addition, m6A modified regions can undergo conformational changes, 
referred to as an “m6A switch”, favoring the interaction with RNA binding proteins, as in the case of 
the splicing regulator HNRNPC [30].  
 
Figure 2. Functional roles of m6A modification on mRNA expression. Most of m6A’s effects on mRNA 
metabolism are mediated by reader proteins whose binding can be directly or indirectly affected by 
m6A. In the nucleus, the direct readers are YTHDC1 and HNRNPA2, which stimulate splicing and 
microRNA processing, respectively. YTHDC1 also stimulates mRNA export. The splicing regulator 
HNRNPC (heterogeneous nuclear ribonucleoprotein) is an indirect reader whose binding is favored 
by structural rearrangement induced by m6A modification. In the cytoplasm, mRNA translation is 
stimulated by the direct reader eIF3, ABCF1 (ATP binding cassette subfamily F member 1), YTHDF1, 
Figure 2. Functional roles of m6A modification on mRNA expression. Most of m6A’s effects on mRNA
metabolism are mediated by reader proteins whose binding can be directly or indirectly affected by
m6A. In the nucleus, the direct readers are YTHDC1 and HNRNPA2, which stimulate splicing and
microRNA processing, respectively. YTHDC1 also stimulates mRNA export. The splicing regulator
HNRNPC (heterogeneous nuclear ribonucleoprotein) is an indirect reader whose binding is favored
by structural rearrangement induced by m6A modification. In the cytoplasm, mRNA translation is
stimulated by the direct reader eIF3, ABCF1 (ATP binding cassette subfamily F member 1), YTHDF1,
YTHDF3 and YTHDC2, while it is inhibited by the indirect reader FMR1. mRNA decay is increased by
the direct readers YTHDF2, YTHDF3 and YTHDC2, while it is inhibited by the direct readers IGF2BPs
(insulin-like growth factor 2 mRNA-binding protein) and the m6A-repelled proteins ELAVL1 (ELAV
like RNA binding protein 1) and G3BPs (G3BP stress granule assembly factor).
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Another crucial step of gene expression that is regulated by m6A is mRNA nuclear export.
Silencing of METTL3 delays mRNA export, while downregulation of ALKBH5 has the opposite effect
and accelerates export [20,31]. The nuclear reader YTHDC1 plays a role in this process recruiting
the mRNA export receptor NXF1 (nuclear RNA export factor 1) through SRSF3 [32]. Once in the
cytoplasm, m6A-modified mRNA is mainly regulated by the YTH reader proteins. In particular,
YTHDF1 promotes translation, while YTHDF2 stimulates mRNA decay by recruiting the translation
initiation factor eIF3 and the CCR4-NOT deadenylase complex, respectively [33,34]. Interestingly,
YTHDF1 and YTHDF2 share a large set of common target mRNAs. These apparently contradictory
effects of the two readers may be required for the expression of transcripts that require rapid and
transient control, such as in the case of gene expression programs that are activated upon responses
to stress and during cellular differentiation. The YTHDF3 reader can cooperate with both YTHDF1
and YTFDF2, thereby promoting both translation and mRNA decay [35,36]. It has been suggested that
YTHDF3 contributes to the RNA binding specificity of YTHDF1 and YTHDF2, which eventually bind
m6A methylated mRNAs as heterodimers [35,36]. Strikingly, YTHDF2 KO mice are embryonically
lethal [37]. While deletion of YTHDF1 does not affect embryo development and it is compatible
with life [38].
YTHDC2 has a dual role in controlling the expression of m6A modified mRNAs, it both enhances
their translation and accelerates their decay [39–41]. In contrast to the other YTH proteins, YTHDC2
contains other functional regions in addition to the YTH domain, including an ATP-dependent RNA
helicases domain interspersed with two Ankyrin repeats, a known protein–protein interaction module
that is responsible for the recruiting of the Xrn1 exoribonuclease [39–41]. In mouse, the protein is
highly expressed in germ cells and is essential for male and female fertility. It has been suggested
that the binding of YTHDC2 can accelerate protein synthesis, as well as rapid mRNA decay, to timely
regulate gene expression during cell differentiation and developmental programs [39–41].
Additional direct m6A cytoplasmic readers, which lack the YTH domain, are the translation
initiation factor eIF3 and the ABCF1 (ATP binding cassette subfamily F member 1) proteins,
which stimulate CAP-independent translation of mRNA m6A-modified in the 5′-UTR [42–44],
and the IGF2BPs (insulin-like growth factor 2 mRNA-binding protein) (IGFBP1, 2 and 3) oncogenic
proteins [45], which increase the stability of modified mRNAs. Thus, the latter have an opposite
role to the YTH reader proteins. Moreover, binding sites for IGF2BPs present a different pattern
compared to the YTH proteins because are enriched in the 3′-UTR. Finally, the negative regulators of
translation FMR1, and its paralogues FXR1 and FXR2, are indirect readers of m6A modified transcripts.
Conversely, the G3BP1, G3BP2 (G3BP stress granule assembly factor) and ELAVL1 (ELAV-like RNA
binding protein 1) (also known as HuR) RNA binding proteins, which stabilize mRNA upon binding,
are indirectly repelled by the m6A modification [23,46]. Altogether, these data show the existence of
a complex network of interactions between m6A modification and RNA-binding proteins that can
regulate mRNA expression at multiple levels.
4. m6A Roles in AML (Acute Myeloid Leukaemia) and Normal Haematopoiesis
Defects in cell differentiation and uncontrolled proliferation are a hallmark of several cancers.
AML represents a remarkable example of malignancy with these features [1]. It is characterized by
an accumulation of immature leukemic cells (also referred to as blasts) in the bone marrow and blood.
This accumulation arises from a failure of myeloid progenitors to mature and respond to normal
regulators of proliferation. Chromosome aberrations, such as translocations, inversions and deletions,
are detectable in about half of AML patients and are utilized for the classification and as prognostic
factors of the disease. Moreover, a number of gene mutations as well as deregulated expression of
genes have been identified and has provided insights into the mechanisms of leukaemogenesis [1].
Noteworthy, cells derived from different AML subtypes can be induced to differentiate by specific
agents into cells that resemble normal counterparts. For this reason, AML cells have been extensively
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utilized for studying the molecular mechanisms that regulate the correct balance between proliferation
and differentiation.
4.1. WTAP (Wilms Tumor 1-Associated Protein) in AML
First clue of the involvement of the m6A modification in cancer was the identification of WTAP
protein as specific interactor of the Wilms’ tumor gene (WT1) [47], even if at that time the complex
responsible for the m6A modification and its role in mRNA metabolism were still unknown. WT1 was
initially discovered as a tumor suppressor gene, but in leukaemia, where it is generally overexpressed
and associated with poor prognosis, it acts as an oncogene [48]. Later on, WTAP protein was found
up-regulated in AML and its downregulation in AML cell lines decreased proliferation, induced
apoptosis and delays leukaemia progression in recipient mice [49]. At the same time, WTAP was
identified as a regulatory factor for the m6A methylation complex [50], at which point m6A modification
becomes the focus of AML studies.
4.2. Core METTL3/METTL14 (Methyltransferase-Like Protein 3/Methyltransferase-Like Protein 14) Complex
in AML
Notably, AML is one of the cancers with the highest levels of both METTL3 and METTL14
expression (data from the Cancer Genome Atlas, TCGA) and, more importantly, METTL3
and METTL14 were found overexpressed in AML cells compared to normal haematopoietic
progenitors [51–54]. Consistent with METTL3 and METTL14 playing an oncogenic role in AML,
overexpression of both genes in AML cell lines and primary blasts increased proliferation, while their
downregulation impaired proliferation and resulted in a strong induction of apoptosis [51–53].
The oncogenic function of m6A was also demonstrated in primary cells derived from an AML
mouse model carrying the oncogenic MLL-AF9 fusion gene and the FLT3 internal tandem duplication
(FLT3-ITD), two chromosomal translocations that characterized aggressive AML subtypes and
that drive AML in mouse. In this case, a genome-wide CRISPR/Cas9 screening identified
METTL3, METTL14 and METTL16 as critical genes for AML survival [52]. More importantly,
the METTL3/METTL14 methylation complex was found to promote the development of AML and
maintain leukaemia-initiating cells in transplantation mouse models [51–53]. These effects of METTL3
and METTL14 in human and mouse AML cells are abolished by catalytic inactive METTL3 or METTL14
mutant impaired in target recognition of the methyltransferase complex, therein, they depend on
the deposition of m6A modification. In AML cells, METTL3 and METTL14 bound predominantly to
transcription start sites, even if METTL3 binding did not always correlate with METTL14, and early
m6A co-transcriptional deposition promoted translation of mRNAs relevant for AML proliferation,
such as c-MYC, BCL2, PTEN, SP1 and MYB [51–53]. The transcription factor CEBPZ (CCAAT enhancer
binding protein), which as an important role in haematopoietic differentiation, was shown to recruit
METTL3 on gene promoters [52]. CEBPZ was identified as a novel recurrently mutated gene in
AML [55,56], suggesting that in this leukaemia might be lost the co-transcriptional recruitment
of METTL3.
Interestingly, even if aberrant alternative splicing plays a relevant role in AML [57] and m6A
modification has an established role in regulating alternative splicing, mRNA translation has been
identified as the main regulatory step deregulated by m6A in AML [51–53]. Therein, the YTHDF1
reader should mediate most of the observed phenotype in AML. However, in view of the pleiotropic
nature of the m6A modification, it is very likely that additional functions for the other m6A readers
will be soon characterized in AML.
In AML, METTL3 has been also shown to be mis localized to the cytoplasm and to associate with
translating ribosomes [54]. Similar results were also found in lung cancer [58]. It was also demonstrated
that cytoplasmic METTL3 can promote translation of specific mRNAs independently from its catalytic
activity [54,58]. Moreover, higher levels of cytoplasmic METTL3 results in concomitant increase of
WTAP protein expression [54]. As WTAP mRNA expression is not elevated in AML [54], this latter
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mechanism might be relevant to increase WTAP protein levels concomitantly to the METTL3/METTL14
core complex and sustain its oncogenic role in AML.
4.3. RBM15 (RNA-binding motif 15) in AML
Another link between m6A and AML comes from RMB15, a component of the MACOM
complex. Some forms of Acute Megakaryoblastic Leukaemia (AMKL), a subtype of paediatric AML
characterized by abnormal megakaryoblasts, carry a chromosomal translocation between RBM15 and
MKL1 [59], a transcription coactivator that regulates the expression of genes involved in cell growth.
Notably, RBM15 directly binds to and controls the alternative splicing of transcripts encoding for
key haematopoietic differentiation genes such as GATA1, RUNX1, c-MPL and TAL1 [60]. Therein,
it is possible to speculate that the RBM15 fusion protein might also affect MACOM function and
produce a deregulation of the m6A modification within transcriptome that will eventually result in
aberrant splicing regulation. Conditional-knockout mice of RBM15 in the haematopoietic compartment
have been generated. Deletion of RBM15 caused a block in B cell differentiation and myeloid
and megakaryocytic expansion [15], indicating that mis regulation of m6A deposition may affect
haematopoietic differentiation in vivo. However, the relationship between RBM15 depletion and m6A
modification in mouse models has not yet been assessed.
4.4. FTO (Fat Mass and Obesity-Associated) in AML
m6A levels depend also on the activity of erasers and readers. Elevated expression of FTO
has been reported in AML subtypes carrying MLL-AF9, PML-RARA and FTL3-ITD translocation,
respectively [61]. Downregulation of FTO in cell models carrying these fusion products decreased their
proliferation capacity. Moreover, it was shown that R-2HG (R-2-hydroxyglutarate), an anti-leukemic
compound that inhibits a series of Fe(II)/a-KG-dependent dioxygenases [62], also targets the FTO
demethylase [63]. In particular, FTO inhibition by R-2HG resulted in decreased expression of the
MYC oncogene and the transcription factor CEBPA. These results are in sharp contrast with the
pro-leukemic roles of METTL3 and METTL14 demonstrated by independent groups, in many cases by
using cells with the same mutations in which the oncogenic role of FTO was demonstrated [51–53].
Moreover, it was shown that the depletion of FTO by CRISPR/cas9 has no effect on AML growth [51]
and the Project DRIVE, a large-scale knockdown screening in cancer cell lines, detected no general
FTO-dependency of leukaemia cells [64]. These discrepancies may be due to the conditions used in
those studies, rather than a specific oncogenic effect of FTO in AML. It should be also pointed out that
there is currently a great debate on the effective contribution of FTO as specific m6A demethylases [65].
4.5. Core METTL3/METTL14 Complex in Normal Haematopoiesis
METTL3 and METTL14 are also highly expressed in mouse and human HSCs (haematopoietic
stem cells), and their expressions decrease during myeloid differentiation [51–53]. As observed in
AML cell lines, METTL3 and METTL14 silencing in human and mouse HSCs reduced proliferation
capacity and stimulated myeloid differentiation [51–53]. Moreover, overexpression of a catalytic active
METTL3 or METLL14 in HSCs promoted proliferation and inhibited myeloid differentiation [51–53],
indicating that increased m6A levels might alter the normal differentiation pathway in HSC, resulting
in accumulation of progenitor cells.
Downregulation of METTL3 in zebrafish embryos and in the mouse aorta-gonad-mesonephros
(AGM), the region of the primary origins of the definitive HSC in vertebrates, strongly affect HSC
production by repressing Notch signaling [66]. It was also shown that the embryonic METTL3
function in the haematopoietic system is mediated by the YTHDF2 dependent decay of Notch
encoding mRNA [66]. Similar results were obtained upon conditional METTL3 KO in the mouse
AGM region [67], therein, indicating an evolutionally conserved function of METTL3 in HSPCs
(haematopoietic stem and progenitor cells) specification in vertebrates. Conditional KO mice of
METTL3 and METTL14 in the adult haematopoietic system have been also produced [53,68]. Strikingly,
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deletion of METTL3 expands the HSCs in adult bone marrow [68], contrary to what occurred in
isolate HSCs, indicating a crucial role for METTL3 in regulating the quiescence of HSCs in vivo.
Surprisingly, this phenotype was not detected upon conditional deletion of METTL14 [68], which is
required for METTL3-mediated m6A modification on target RNAs. However, in transplantation
experiments, mouse HSCs deleted for METTL3 or METTL14 showed reduced repopulation ability
and the deletion of METTL14 from primary leukaemia blasts significantly delayed leukaemia onset in
recipient mice [38,68]. Notably, the downregulation of the m6A methylation complex in normal HSCs
did not induce massive apoptosis as observed in AML [51,53,66,68], even if the molecular mechanism
responsible for this different behavior is still not completely clear. In view of this, it is tempting to
speculate that AML cells will show higher sensitivity to future chemical inhibitors of the m6A writing
complex than normal HSCs providing new therapeutic options for AML treatment.
5. Conclusions
Advances in the understanding of AML pathogenesis have been remarkable in these years,
but treatment has changed little in the past decades and is mainly based on chemotherapy. Moreover,
in AML patients, relapse is frequent and generally accompanied by very poor prognosis. For this reason,
many studies are now focusing on the development of new treatments that may flank, replace or follow
standard therapy. Epigenetic modifications to histones and DNA have established roles in normal
haematopoietic development and leukaemia. More importantly, epigenetic drugs that specifically
target these modifications are currently in clinical trials for the treatment of AML. Until recently,
little attention has been given to understanding the role of RNA chemical modifications and its
contribution to human cancer, even if their presence within different RNA species have been known
for decades. The explosion of epitranscriptomics is deeply changing our approaches to cancer biology
studies. In the last year, we have assisted in many acclaimed revolutions in the RNA field that have
deeply transformed our understanding of how gene expression is regulated; however, none of these
has led to major innovations in tumor therapies. Even if the road ahead is still long, it appears to
be different this time with epitranscriptomics. Currently, alteration of m6A levels has been found
to be closely associated with various kinds of cancers and to play important roles in metastasis and
drug resistance [69,70]. AML has indicated how alteration of m6A modification can disrupt normal
cellular differentiation and contribute to cancer development. In analogy with epigenetic modifications,
it is predictable that the activity of the m6A modifying enzymes might be easily targetable by chemical
compounds and may, eventually, provide major innovations in future cancer therapies. In this regard,
AML is paving the way.
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CEBP CCAAT enhancer binding protein
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ELAVL1 ELAV like RNA binding protein 1
G3BP G3BP stress granule assembly factor
hnRNP Heterogeneous nuclear ribonucleoprotein
HSC Haematopoietic stem cell
HSPC Haematopoietic stem and progenitor cells
IGF2BP Insulin-like growth factor 2 mRNA-binding protein
KO Knock-out
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